| Year |
Citation |
Score |
| 2019 |
Mullen M, Quinn J, Greenwade M, Opara G, Beck-Noia H, Hagemann I, Hagemann A, Kuroki L, McCourt C, Thaker P, Powell M, Mutch D, Fuh K. AXL in metastatic ovarian cancer tumors is a targetable biomarker associated with chemoresistance and poor prognosis Gynecologic Oncology. 154: 79-80. DOI: 10.1016/J.Ygyno.2019.04.188 |
0.303 |
|
| 2017 |
Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, et al. Breast cancer neoantigens can induce CD8 T cell responses and antitumor immunity. Cancer Immunology Research. PMID 28619968 DOI: 10.1158/2326-6066.Cir-16-0264 |
0.322 |
|
| 2016 |
Divine LM, Nguyen MR, Meller E, Desai RA, Arif B, Rankin EB, Bligard KH, Meyerson C, Hagemann IS, Massad M, Thaker PH, Hagemann AR, McCourt CK, Powell MA, Mutch DG, et al. AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget. PMID 27764792 DOI: 10.18632/Oncotarget.12637 |
0.308 |
|
| 2015 |
Hagemann IS, O'Neill PK, Erill I, Pfeifer JD. Diagnostic yield of targeted next generation sequencing in various cancer types: An information-theoretic approach. Cancer Genetics. PMID 26227479 DOI: 10.1016/J.Cancergen.2015.05.030 |
0.334 |
|
| 2015 |
Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. American Journal of Clinical Pathology. 143: 768-77. PMID 25972318 DOI: 10.1309/Ajcphwacttuyj7Dd |
0.335 |
|
| 2015 |
Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 121: 631-9. PMID 25345567 DOI: 10.1002/Cncr.29089 |
0.304 |
|
| 2014 |
Sehn JK, Hagemann IS, Pfeifer JD, Cottrell CE, Lockwood CM. Diagnostic utility of targeted next-generation sequencing in problematic cases. The American Journal of Surgical Pathology. 38: 534-41. PMID 24451277 DOI: 10.1097/Pas.0000000000000161 |
0.316 |
|
| 2014 |
Hagemann IS, Govindan R, Javidan-Nejad C, Pfeifer JD, Cottrell CE. Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: e12-6. PMID 24419427 DOI: 10.1097/Jto.0B013E3182A7D22E |
0.331 |
|
| 2013 |
Hagemann IS, Al-Kateb H, Cottrell CE, Lockwood C, Nguyen T, Spencer D, Bredemeyer A, Head R, Varghese N, Nagarajan R, Seibert K, Duncavage EJ, Kulkarni S, Pfeifer JD. Abstract 813: Diagnostic yield of targeted next-generation sequencing for personalized cancer therapeutics. Cancer Research. 73: 813-813. DOI: 10.1158/1538-7445.Am2013-813 |
0.336 |
|
| 2013 |
Zsiros E, Lee H, Hagemann IS, Duttagupta P, Frank R, Garrabrant T, Levine BL, June CH, Tanyi J, Kandalaft L, Feldman M, Coukos G. Abstract 3968: Ovarian cancer chemokine microenvironment is conducive to homing of CD3/CD28 co-stimulated T cells prepared for adoptive transfer therapy. Cancer Research. 73: 3968-3968. DOI: 10.1158/1538-7445.Am2013-3968 |
0.344 |
|
| 2012 |
Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. Plos One. 7: e49829. PMID 23189165 DOI: 10.1371/Journal.Pone.0049829 |
0.351 |
|
| 2012 |
Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 633-43. PMID 22127019 DOI: 10.1038/Mt.2011.256 |
0.328 |
|
| 2012 |
Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic Oncology. 124: 192-8. PMID 22040834 DOI: 10.1016/J.Ygyno.2011.09.039 |
0.311 |
|
| 2011 |
Hoyt CC, Hagemann IS, Hagemann AR, Wang L, Hung E, Lane K, Coukos G, Feldman MD. Performance characteristics and validation of automated tumor-infiltrating lymphocyte counting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10562. PMID 28021887 DOI: 10.1200/Jco.2011.29.15_Suppl.10562 |
0.308 |
|
| 2011 |
Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ, Feldman MD, Coukos G. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biology & Therapy. 12: 367-77. PMID 21785280 DOI: 10.4161/Cbt.12.4.16908 |
0.313 |
|
| 2008 |
Hagemann IS, Miller DL, Klco JM, Nikiforovich GV, Baranski TJ. Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling. The Journal of Biological Chemistry. 283: 7763-75. PMID 18195008 DOI: 10.1074/Jbc.M709467200 |
0.678 |
|
| 2007 |
Hagemann IS, Narzinski KD, Baranski TJ. E2F8 is a nonreceptor activator of heterotrimeric G proteins. Journal of Molecular Signaling. 2: 3. PMID 17394670 DOI: 10.1186/1750-2187-2-3 |
0.59 |
|
| 2006 |
Hagemann IS, Narzinski KD, Floyd DH, Baranski TJ. Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking. The Journal of Biological Chemistry. 281: 36783-92. PMID 17023413 DOI: 10.1074/Jbc.M607686200 |
0.661 |
|
| 2006 |
Hagemann IS, Nikiforovich GV, Baranski TJ. Comparison of the retinitis pigmentosa mutations in rhodopsin with a functional map of the C5a receptor. Vision Research. 46: 4519-31. PMID 16962629 DOI: 10.1016/J.Visres.2006.07.010 |
0.621 |
|
| Show low-probability matches. |